Navigation Links
Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
Date:5/4/2010

s, smallpox, HIV and hepatitis C.  An accomplished veteran in the biotechnology industry, Ken's depth of experience is vital as Chimerix matures to focus on the commercial positioning of the company's novel antiviral product candidates."

Mr. Moch has played an integral role in building several life science companies, having previously led Alteon Inc. and Biocyte Corporation as Chief Executive Officer.  He also served as Managing Director, Healthcare Banking at ThinkEquity Partners.  Mr. Moch was a co-founder and Vice President of The Liposome Company, Inc. (acquired by Elan), and earlier in his career, he was a management consultant with McKinsey & Company, Inc.  He holds an A.B. degree in biochemistry from Princeton University and an MBA from the Stanford Graduate School of Business.

"I am honored to assume this responsibility as Chimerix is well positioned as an emerging leader in antiviral drug development.  With a pipeline of potent antiviral medicines, a technology capable of radically improving the pharmacological properties of drug candidates, a chemical library generating NCEs and an outstanding scientific and clinical team, this is the right time to accelerate development and partnering activities," said Mr. Moch.  "I look forward to the development of our lead clinical-stage candidates, CMX001 and CMX157, and to advancing promising new antiviral compounds into the clinic alone and in conjunction with future partners."

Dr. Painter led Chimerix as President and Chief Executive Officer since its founding in 2002.  Dr. Painter has more than 31 years of experience in pharmaceutical development, having served as a founding member of the Triangle Pharmaceuticals management team, where he was Executive Vice President, Research and Development.  Prior, he was Director of Chemistry and Director of Vir
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
2. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
3. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
4. Chimerix Joins International Network of Organizations to Cure Malaria
5. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
6. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
7. KGI Names Kerry Howell Vice President for Advancement
8. Vical Names Andrew de Guttadauro Vice President, Corporate Development
9. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. CryoLife Names Philip Theodore as Vice President, General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... North Shore Towers, a luxury co-op community ... Energy, one of the nation’s leading combined heating and power ... its 43-year-old CHP system. The original CHP system had been ... extend the life of the plant, GI Energy was contracted ... heat recovery equipment, while maintaining continuous operation of the entire ...
(Date:7/31/2014)... SAN DIEGO, July 31, 2014 ... a leading company using proprietary taste science technologies ... for the food, beverage, and ingredient supply industries, ... 2014.  The Company ended the second quarter with ... "During the past quarter Senomyx ...
(Date:7/31/2014)... Rancho BioSciences , the scientific ... Array Suite with tranSMART . Scientists that ... send data in tranSMART to Array Suite for further ... tranSMART including the new 1.2 release. Array Suite ... for the analysis of high dimensional quantification data, including ...
(Date:7/31/2014)... BOTHELL, Wash. , July 31, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... Company,s second quarter 2014 financial results will be released ... will host a conference call and live webcast at ...
Breaking Biology Technology:North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2
... , IRVINE, Calif. , April 26 ... products chemistry company which provides novel and innovative ingredients ... announced today the launch of pTeroPure™ pterostilbene(tero-STILL-bean). This exciting ... an exclusive worldwide license to all patent rights of ...
... SAN DIEGO , April 26 ... the discovery and development of RNA-targeted therapies, today announced ... research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type ... high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) ...
... 23 Asymchem Laboratories is proud to announce and welcome Dr. ... Huang as Director of Chemical Development, and Dr. Xiaojun Huang ... , , ... February 1, 2010 .  He brings extensive scientific and managerial experience in ...
Cached Biology Technology:ChromaDex Launches pTeroPure Pterostilbene 2ChromaDex Launches pTeroPure Pterostilbene 3ChromaDex Launches pTeroPure Pterostilbene 4ChromaDex Launches pTeroPure Pterostilbene 5Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 2Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 3Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 4Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 5Asymchem Laboratories Hires Three New Employees: Guojie Xu, Pingzhong Huang, and Xiaojun Huang 2
(Date:7/31/2014)... research, supported by the National Science Foundation (NSF), ... uniformly accelerates atmospheric warming, indicating instead that certain ... emit into the atmosphere. , The study, ... , focuses on thermokarst lakes, which occur as ... with melted fresh water, converting what was previously ...
(Date:7/31/2014)... A long-term follow-up study (HPV-023; NCT00518336) shows ... GlaxoSmithKline,s human papilloma virus (HPV) vaccine Cervarix. ... were followed for more than nine years, ... was 100%. This is the longest follow-up ... https://www.landesbioscience.com/journals/vaccines/article/29532/ for the full paper. ...
(Date:7/31/2014)... of animal models against the highly infectious and virulent ... disease that kills approximately 30,000 Americans annually. The research ... Immunity . , In the study, the vaccine ... toxins produced by C. difficile , as well ... that mimics the human disease, after only two immunizations. ...
Breaking Biology News(10 mins):Certain Arctic lakes store more greenhouse gases than they release 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2
... PA, June 24, 2011 Adolescents who diet and ... behaviors and binge eating) carry these unhealthy practices into ... by University of Minnesota researchers and published in the ... American Dietetic Association . "The findings from the ...
... are widely recognized as significant environmental concerns in the ... major impact of landscape irrigation on their regional water ... in College Station, Texas, estimated that more than 24 ... annually for landscape irrigation alone. According to the ...
... June 23, 2011 UT Southwestern Medical Center researchers ... pathway in Huntington,s disease, a finding that may eventually ... the progression of degenerative nerve disorders. "Our studies ... treatment and possibly for other neurodegenerative diseases," said Dr. ...
Cached Biology News:Adolescents' dieting and disordered eating behaviors continue into young adulthood 2Adolescents' dieting and disordered eating behaviors continue into young adulthood 3Landscape coefficients prove useful for urban water conservation efforts 2Compound may provide drug therapy approach for Huntington's disease 2
... Columns are designed for the rapid purification of ... agarose gels. The DNA band is excised from ... Embedded within the base of the column are ... agarose and impurities back while allowing DNA to ...
... Ultra Agarose Spin Kit is an advanced system for ... purified DNA can be used directly for any downstream ... DNA is ready to use in 56 minutes ... used for TAE and TBE gels No specialised ...
This depletion cocktail is tailored to deplete IgE-bearing (I.e. basophils and mast cells) from whole blood...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human HLA-DR TAC is designed to deplete human HLA-DR from samples to isolate resting CD4+ or CD8+ T cells....
Biology Products: